A.N. DAKUKO^1, 2, A.YU. ZAVAGINA¹, E.B. PAVLINOVA¹, E.S. SOKOLOVA², A.G. KUNGURTSEVA²

 ¹Omsk State Medical University, Omsk

²Regional Children’s Clinical Hospital, Omsk

Contact details:

Dakuko A.N. — PhD (Medicine), Associate Professor of the Department of Hospital Pediatrics

Address: 12 Lenin St., 644099 Omsk, Russian Federation, tel.: +7-932-325-07-22, e-mail: doc-man85@mail.ru

Hurler syndrome is the most severe form of metabolic genetic disease, mucopolysaccharidosis (MPS) type I, caused by a mutation of the IDUA gene (the gene encoding the alpha-L-iduronidase enzyme). This year in the Omsk region, a case of MPS type I (Hurler syndrome) was diagnosed in a girl V., 2.5 years old, so far the only one in the region. Late diagnosis of MPS type I does not allow to receive the necessary amount of therapy, which leads to a more severe course of this multisystem disease with the formation of complications and a decrease in the patient’s quality of life. This fact determines the relevance of the problem. Despite the relative rarity of this pathology, timely diagnosis is very important. The gold standard of treatment is hematopoietic stem cell transplantation (HSCT). This method is associated with a number of complications, so therapy should be started before the clinically complete picture of the disease, namely, before the age of 2. The earlier HSCT is performed, the better the cognitive functions and somatic manifestations are. However, even timely treatment does not guarantee that the patient is free from the burden of the disease. Along with this, enzyme replacement therapy with laronidase is widely used, but it is ineffective in Hurler syndrome. This determines the need to consider other strategies to improve treatment outcomes. Scientific research into early screening methods and more effective therapy with genetic engineering technologies is actively ongoing.

Key words: mucopolysaccharidosis, Hurler syndrome, diagnosis, treatment, neonatal screening, gene therapy.

 REFERENCES

1. Kubaski F., de Oliveira Poswar F., Michelin-Tirelli K. et al. Diagnosis of mucopolysaccharidoses. Diagnostics, 2020, vol. 10 (3), p. 172. DOI: 10.3390/diagnostics10030172
2. Pierzynowska K., Gaffke L., Cyske Z. et al. Oxidative stress in mucopolysaccharidoses: pharmacological implications. Molecules, 2021, vol. 26 (18), p. 5616. DOI: 10.3390/molecules26185616
3. Hampe C.S., Eisengart J.B., Lund T.C. et al. Mucopolysaccharidosis type i: a review of the natural history and molecular pathology. Cells, 2020, vol. 9 (8), p. 1838. DOI: 10.3390/cells9081838
4. Rylova N.V., Shakirova A.A., Khusainova A.R. et al. Mucopolysaccharidosis type I — Hurler syndrome. Prakticheskaya meditsina, 2020, vol. 18, no. 1, pp. 128–131 (in Russ.).
5. Vashakmadze N.D., Kostik M.M., Zhurkova N.V. et al. Characteristics of joint syndrome in children with mucopolysaccharidosis type I. Voprosy sovremennoy pediatrii, 2021, vol. 20, no. S6, pp. 567–575 (in Russ.).
6. Aldenhoven M., Wynn R.F., Orchard P.J. et al. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood, 2015, vol. 125 (13), pp. 2164–2172. DOI: 10.1182/blood-2014-11-608075
7. Gupta R., Goyal M., Tiwari R., Bhandari A. Ventriculoperitoneal shunt and bilateral herniotomies in mucopolysaccharidosis type I: A surgical challenge. Saudi J. Health Sci, 2024, vol. 13 (2), pp. 156–161. DOI: 10.4103/sjhs.sjhs_65_24
8. Kankasova M.N., Mokhova O.G., Pozdeeva O.S. Hepatosplenic syndrome in pediatric practice. Prakticheskaya meditsina, 2017, vol. 10, no. 111, pp. 16–21 (in Russ.).
9. Kubaski F., de Oliveira Poswar F., Michelin-Tirelli K. et al. Mucopolysaccharidosis type I. Diagnostics, 2020, vol. 10 (3), p. 161. DOI: 10.3390/diagnostics10030161
10. Galimberti C., Madeo A., Di Rocco M. et al. Mucopolysaccharidoses: early diagnostic signs in infants and children. Ital. J. Pediatr, 2018, vol. 44 (suppl 2), p. 133. DOI: 10.1186/s13052-018-0550-5
11. Arn P., Bruce I.A., Wraith J.E. et al. Airway-related symptoms and surgeries in patients with mucopolysaccharidosis I. Ann. Otol. Rhinol. Laryngol, 2015, vol. 124 (3), pp. 198–205. DOI: 10.1177/0003489414550154
12. Schmidt M., Breyer S., Löbel U. et al. Musculoskeletal manifestations in mucopolysaccharidosis type I (Hurler syndrome) following hematopoietic stem cell transplantation. Orphanet J. Rare Dis, 2016, vol. 11, p. 93. DOI: 10.1186/s13023-016-0470-7
13. Pillai N.R., Ahmed A., Vanyo T., Whitley C.B. Early neonatal cardiac phenotype in Hurler syndrome: case report and literature review. Genes, 2022, vol. 13 (8), p. 1293. DOI: 10.3390/genes13081293
14. Tomatsu S., Pitz S., Hampel U. Ophthalmological findings in mucopolysaccharidoses. J. Clin. Med, 2019, vol. 8 (9), p. 1467. DOI: 10.3390/jcm8091467
15. Lin H.-Y., Lee C.-L., Lo Y.-T. et al. An at-risk population screening program for mucopolysaccharidoses by measuring urinary glycosaminoglycans in Taiwan. Diagnostics, 2019, vol. 9 (4), p. 140. DOI: 10.3390/diagnostics9040140
16. Leal A.F., Nieto W.G., Candelo E. et al. Hematological findings in lysosomal storage disorders: a perspective from the medical laboratory. EJIFCC, 2022, vol. 33 (1), pp. 28–42.
17. Lin S.P., Lin H.Y., Wang T.J. et al. A pilot newborn screening program for Mucopolysaccharidosis type I in Taiwan. Orphanet J. Rare Dis, 2013, vol. 8, p. 147. DOI: 10.1186/1750-1172-8-147
18. Alsharhan H., Haider M.Z., Qadoura B. et al. Enzymatic testing for mucopolysaccharidosis type I in Kuwaiti newborns: a preliminary study toward newborn screening. Front. Pediatrics, 2024, vol. 12. DOI: 10.3389/fped.2024.1376053
19. Gragnaniello V., Cazzorla C., Gueraldi D. et al. Light and shadows in newborn screening for lysosomal storage disorders: eight years of experience in Northeast Italy. Int. J. Neonatal Screen, 2024, vol. 10 (1), p. 3. DOI: 10.3390/ijns10010003
20. Ames E.G., Fisher R., Kleyn M., Ahmad A. Current practices for U.S. Newborn screening of pompe disease and MPSI. Int. J. Neonatal Screen, 2020, vol. 6 (3), p. 72. DOI: 10.3390/ijns6030072
21. Burlina A.B., Gragnaniello V. Newborn screening of mucopolysaccharidosis type I. Crit. Rev. Clin. Lab. Sci, 2022, vol. 59 (4), pp. 257–277. DOI: 10.1080/10408363.2021.2021846
22. Donati M.A., Pasquini E., Spada M. et al. Newborn screening in mucopolysaccharidoses. Ital. J. Pediatr, 2018, vol. 44, pp. 25–34. DOI: 10.1186/s13052-018-0552-3
23. Peck D.S., Lacey J.M., White A.L. et al. Incorporation of second-tier biomarker testing improves the specificity of newborn screening for mucopolysaccharidosis type I. Int. J. Neon. Screen, 2020, vol. 6 (1), p. 10. DOI: 10.3390/ijns6010010
24. Clarke L.A., Dickson P., Ellinwood N.M., Klein T.L. Newborn screening for mucopolysaccharidosis i: moving forward learning from experience. Int. J. Neon. Screen, 2020, vol. 6 (4), p. 91. DOI: 10.3390/ijns6040091
25. Clarke L.A., Atherton A.M., Burton B.K. et al. Mucopolysaccharidosis type I newborn screening: best practices for diagnosis and management. J. Pediatr, 2017, vol. 182, pp. 363–370. DOI: 10.1016/j.jpeds.2016.11.036
26. Clarke L.A., Giugliani R., Guffon N. et al. Genotype-phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I Registry. Clin. Genet, 2023. DOI: 10.1111/cge.13583
27. Mikhaylova S.V., Slatetskaya A.N., Pristanskova E.A. et al. Mucopolysaccharidosis type I: modern approaches to therapy. Voprosy gematologii/onkologii i immunopatologii v pediatrii, 2019, vol. 17, no. 4, pp. 35–42 (in Russ.).
28. Eisengart J.B., Rudser K.D., Xue Y. et al. Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison. Genet. Med, 2018, vol. 20 (12), pp. 1423–1429. DOI: 10.1038/gim.2018.29
29. Vashakmadze N.D., Namazova-Baranova L.S., Zhurkova N.V. et al. Results of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Hurler syndrome: clinical cases. Voprosy sovremennoy pediatrii, 2019, T. 18, № 3, C. 196–202.
30. Babushkin A.E., Khusnutdinova E.G., Ryskulova E.K. et al. Rare cases of mucopolysaccharidosis type I in children with Hurler and Hurler-Scheie syndromes. Rossiyskiy oftal’mologicheskiy zhurnal, 2018, vol. 11, no. 1, pp. 53–58 (in Russ.).
31. Kunin-Batson A.S., Shapiro E.G., Rudser K.D. et al. Long-term cognitive and functional outcomes in children with mucopolysaccharidosis (MPS)-IH (Hurler syndrome) treated with hematopoietic cell transplantation. JIMD Rep, 2016, vol. 29, pp. 95–102. DOI: 10.1007/8904_2015_521
32. Gardin A., Castelle M., Pichard S. et al. Long term follow-up after haematopoietic stem cell transplantation for mucopolysaccharidosis type IH: a retrospective study of 51 patients. Bone Marrow Transplant, 2023, vol. 58 (3), pp. 295–302. DOI: 10.1007/8904_2015_521
33. Azario I., Pievani A., Del Priore F. et al. Neonatal umbilical cord blood transplantation halts skeletal disease progression in the murine model of MPS-I. Sci. Rep, 2017, vol. 7 (1), p. 9473. DOI: 10.1038/s41598-017-09958-9
34. Loeb A.M., Pattwell S.S., Meshinchi S. et al. Donor bone marrow–derived macrophage engraftment into the central nervous system of patients following allogeneic transplantation. Blood Adv, 2023, vol. 7 (19), pp. 5851–5859. DOI: 10.1182/bloodadvances.2023010409
35. Hampe C.S., Wesley J., Lund T.C., Orchard P.J. et al. Mucopolysaccharidosis type I: current treatments, limitations, and prospects for improvement. Biomolecules, 2021, vol. 11 (2), p. 189. DOI: 10.3390/biom11020189
36. Gupta A., Downey M., Shanley R. et al. Reduced-toxicity (BuFlu) conditioning is better tolerated but has a higher second transplantation rate compared to myeloablative conditioning (BuCy) in children with inherited metabolic disorders. Biol. Blood Marrow Transplant, 2020, vol. 26 (3), pp. 486–492. DOI: 10.1016/j.bbmt.2019.11.014
37. Namazova-Baranova L.S., Vashakmadze N.D., Babaykina M.A. et al. Efficiency of modern methods of treatment of patients with mucopolysaccharidosis type I. Pediatricheskaya farmakologiya, 2014, vol. 11, no. 6, pp. 76–79 (in Russ.).
38. Jameson E., Jones S., Remmington T. Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I. Cochrane Database Syst. Rev, 2019, vol. 6. Art. CD009354. DOI: 10.1002/14651858.CD009354.pub5
39. Giugliani R., Giugliani L., de Oliveira Poswar F. et al. Neurocognitive and somatic stabilization in pediatric patients with severe mucopolysaccharidosis type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1–2 trial. Orphanet. J. Rare Dis, 2018, vol. 13, p. 110. DOI: 10.1186/s13023-018-0849-8
40. Pardridge W.M., Boado R.J., Giugliani R. et al. Plasma pharmacokinetics of valanafusp alpha, a human insulin receptor antibody-iduronidase fusion protein, in patients with mucopolysaccharidosis type I. BioDrugs, 2018, vol. 32, pp. 169–176. doi: 10.1007/s40259-018-0264-7
41. Fraldi A., Serafini M., Sorrentino N.C. et al. Gene therapy for mucopolysaccharidoses: in vivo and ex vivo approaches. Ital. J. Pediatr, 2018, vol. 44 (Suppl 2), pp. 130. DOI: 10.1186/s13052-018-0565-y
42. Ellison S., Parker K.H., Bigger B. Advances in therapies for neurological lysosomal storage disorders. J. Inherit. Metab. Dis, 2023, vol. 46 (5), pp. 874–905. DOI: 10.1002/jimd.12615
43. Wu X., He X., Liu F. et al. Development and clinical translation of ex vivo gene therapy. Comput. Struct. Biotechnol. J, 2022, vol. 20, pp. 2986–3003. DOI: 10.1016/j.csbj.2022.06.015
44. Gentner B., Tucci F., Galimberti S. et al. Ex vivo hematopoietic stem cell gene therapy for mucopolysaccharidosis type I (Hurler syndrome). Mol. Genet. Metab, 2021, vol. 132, pp. 42–43.
45. Gentner B., Tucci F., Galimberti S., Fumagalli F. et al. Hematopoietic stem-and progenitor-cell gene therapy for Hurler syndrome. N. Engl. J. Med, 2021, vol. 385 (21), pp. 1929–1940. DOI: 10.1056/NEJMoa2106596
46. Belur L.R., Romero M., Lee J., Podetz-Pedersen K.M. et al. Comparative effectiveness of intracerebroventricular, intrathecal, and intranasal routes of AAV9 vector administration for genetic therapy of neurologic disease in murine mucopolysaccharidosis type I. Front. Mol. Neurosci, 2021, vol. 14. 618360. DOI: 10.3389/fnmol.2021.618360
47. Wang R.Y.J., Kan S.H., Zhang H. et al. Intra-articular AAV9 α-l-iduronidase gene replacement in the canine model of mucopolysaccharidosis type I. Adv. Cell Genet Ther, 2023, vol. 2023 (1). 7419017. DOI: 10.1155/2023/7419017
48. Miyadera K., Conatser L., Llanga T.A., et al. Intrastromal gene therapy prevents and reverses advanced corneal clouding in a canine model of mucopolysaccharidosis I. Mol. Ther, 2020, vol. 28 (6), pp. 1455–1463. DOI: 10.1016/j.ymthe.2020.04.004
49. Harmatz P., Prada C.E., Burton B.K. et al. First-in-human in vivo genome editing via AAV-zinc-finger nucleases for mucopolysaccharidosis I/II and hemophilia B. Mol. Ther, 2022, vol. 30 (12), pp. 3587–3600. DOI: 10.1016/j.ymthe.2022.10.010
50. Hordeaux J., Hinderer C., Goode T. et al. Toxicology study of intra-cisterna magna adeno-associated virus 9 expressing human alpha-L-iduronidase in rhesus macaques. Mol. Ther. Methods Clin. Dev, 2018, vol. 10, pp. 79–88. DOI: 10.1016/j.omtm.2018.06.003